Cardiac amyloidosis MRI: Difference between revisions

Jump to navigation Jump to search
Line 10: Line 10:
* Global subendocardial signal enhancement in the late washout phase (late gadolinium enhancement [LGE]) during delayed enhanced imaging. This finding is strongly suggestive of cardiac amyloid as it is rarely seen in other [[cardiomyopathy|cardiomyopathies]].<ref name="pmid18325442">{{cite journal |author=Vogelsberg H, Mahrholdt H, Deluigi CC, ''et al.'' |title=Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy |journal=[[Journal of the American College of Cardiology]] |volume=51 |issue=10 |pages=1022–30 |year=2008 |month=March |pmid=18325442 |doi=10.1016/j.jacc.2007.10.049 |url=}}</ref>
* Global subendocardial signal enhancement in the late washout phase (late gadolinium enhancement [LGE]) during delayed enhanced imaging. This finding is strongly suggestive of cardiac amyloid as it is rarely seen in other [[cardiomyopathy|cardiomyopathies]].<ref name="pmid18325442">{{cite journal |author=Vogelsberg H, Mahrholdt H, Deluigi CC, ''et al.'' |title=Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy |journal=[[Journal of the American College of Cardiology]] |volume=51 |issue=10 |pages=1022–30 |year=2008 |month=March |pmid=18325442 |doi=10.1016/j.jacc.2007.10.049 |url=}}</ref>
* Increased gadolinium wash-out time
* Increased gadolinium wash-out time
* Abnormal myocardial and blood-pool gadolinium kinetics
* Brighter appearance of the myocardium compared to normal [[myocardium]]
* Brighter appearance of the myocardium compared to normal [[myocardium]]



Revision as of 13:23, 5 May 2013

Cardiac amyloidosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Cardiac Amyloidosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Cardiac amyloidosis MRI On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cardiac amyloidosis MRI

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cardiac amyloidosis MRI

CDC onCardiac amyloidosis MRI

Cardiac amyloidosis MRI in the news

Blogs on Cardiac amyloidosis MRI

Directions to Hospitals Treating Cardiac amyloidosis

Risk calculators and risk factors for Cardiac amyloidosis MRI

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Raviteja Guddeti, M.B.B.S. [2]; Aarti Narayan, M.B.B.S [3]

Overview

Amyloidosis is an infiltrative disease resulting in deposition of amyloid in the extracellular spaces of the tissues. Amyloid infiltration of the heart leads to expansion of these extracellular spaces resulting in retainment of gadolinium dye during cardiac magnetic resonance imaging. This retainment of gadolinium leads to signal enhancement in the late washout phase during delayed enhanced cardiac imaging.

Cardiac MRI

CMR findings in cardiac amyloidosis include:[1][2][3][4][5][6]

  • Global subendocardial signal enhancement in the late washout phase (late gadolinium enhancement [LGE]) during delayed enhanced imaging. This finding is strongly suggestive of cardiac amyloid as it is rarely seen in other cardiomyopathies.[7]
  • Increased gadolinium wash-out time
  • Abnormal myocardial and blood-pool gadolinium kinetics
  • Brighter appearance of the myocardium compared to normal myocardium

CMR has a sensitivity of 88% and a specificity of 95% in the diagnosis and is considered the most accurate predictor of biopsy positive cardiac amyloidosis.

Advantages

  • More sensitive than echo as LGE can be present in patients with amyloidosis with normal ventricular wall thickness also.

Dis-advantages

ACC/AHA Guidelines- ACCF/ACR/AHA/NASCI/SCMR 2010 Expert Consensus Document on Cardiovascular Magnetic Resonance[8] (DO NOT EDIT)

CMR may be used for assessment of patients with LV dysfunction or hypertrophy or suspected forms of cardiac injury not related to ischemic heart disease. When the diagnosis is unclear, CMR may be considered to identify the etiology of cardiac dysfunction in patients presenting with heart failure, including

References

  1. Austin BA, Tang WH, Rodriguez ER; et al. (2009). "Delayed hyper-enhancement magnetic resonance imaging provides incremental diagnostic and prognostic utility in suspected cardiac amyloidosis". JACC. Cardiovascular Imaging. 2 (12): 1369–77. doi:10.1016/j.jcmg.2009.08.008. PMID 20083070. Unknown parameter |month= ignored (help)
  2. Maceira AM, Joshi J, Prasad SK; et al. (2005). "Cardiovascular magnetic resonance in cardiac amyloidosis". Circulation. 111 (2): 186–93. doi:10.1161/01.CIR.0000152819.97857.9D. PMID 15630027. Unknown parameter |month= ignored (help)
  3. Ruberg FL, Appelbaum E, Davidoff R; et al. (2009). "Diagnostic and prognostic utility of cardiovascular magnetic resonance imaging in light-chain cardiac amyloidosis". The American Journal of Cardiology. 103 (4): 544–9. doi:10.1016/j.amjcard.2008.09.105. PMC 2680134. PMID 19195518. Unknown parameter |month= ignored (help)
  4. Maceira AM, Prasad SK, Hawkins PN, Roughton M, Pennell DJ (2008). "Cardiovascular magnetic resonance and prognosis in cardiac amyloidosis". Journal of Cardiovascular Magnetic Resonance : Official Journal of the Society for Cardiovascular Magnetic Resonance. 10: 54. doi:10.1186/1532-429X-10-54. PMC 2605441. PMID 19032744.
  5. Hosch W, Bock M, Libicher M; et al. (2007). "MR-relaxometry of myocardial tissue: significant elevation of T1 and T2 relaxation times in cardiac amyloidosis". Investigative Radiology. 42 (9): 636–42. doi:10.1097/RLI.0b013e318059e021. PMID 17700279. Unknown parameter |month= ignored (help)
  6. Sparrow P, Amirabadi A, Sussman MS, Paul N, Merchant N (2009). "Quantitative assessment of myocardial T2 relaxation times in cardiac amyloidosis". Journal of Magnetic Resonance Imaging : JMRI. 30 (5): 942–6. doi:10.1002/jmri.21918. PMID 19780184. Unknown parameter |month= ignored (help)
  7. Vogelsberg H, Mahrholdt H, Deluigi CC; et al. (2008). "Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy". Journal of the American College of Cardiology. 51 (10): 1022–30. doi:10.1016/j.jacc.2007.10.049. PMID 18325442. Unknown parameter |month= ignored (help)
  8. American College of Cardiology Foundation Task Force on Expert Consensus Documents. Hundley WG, Bluemke DA, Finn JP, Flamm SD, Fogel MA; et al. (2010). "ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents". Circulation. 121 (22): 2462–508. doi:10.1161/CIR.0b013e3181d44a8f. PMC 3034132. PMID 20479157.


Template:WikiDoc Sources